Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population

Transgender men and women represent about 0.6 -1.1%% of the general population. Gender affirming hormone therapy (GAHT) helps ameliorate gender dysphoria and promote well-being. However, these treatments’ cardiovascular (CV) effects are difficult to evaluate due to the limited number of extensive lo...

Full description

Bibliographic Details
Main Authors: Gloria Aranda, Irene Halperin, Esther Gomez-Gil, Felicia A. Hanzu, Núria Seguí, Antonio Guillamon, Mireia Mora
Format: Article
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Endocrinology
Online Access: